Generic Eohilia Availability
Last updated on Apr 10, 2025.
Eohilia is a brand name of budesonide, approved by the FDA in the following formulation(s):
EOHILIA (budesonide - suspension;oral)
-
Manufacturer: TAKEDA PHARMS USA
Approval date: February 9, 2024
Strength(s): 2MG/10ML [RLD]
Is there a generic version of Eohilia available?
No. There is currently no therapeutically equivalent version of Eohilia available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eohilia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions for the treatment of gastrointestinal inflammation
Patent 10,293,052
Issued: May 21, 2019
Inventor(s): Phillips Elaine & Hill Malcolm
Assignee(s): MERITAGE PHARMA, INC.Provided herein are methods for treating, preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
Patent expiration dates:
- November 22, 2028✓
- November 22, 2028
-
Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
Patent 11,197,822
Issued: December 14, 2021
Inventor(s): Dohil; Ranjan et al.
Assignee(s): The Regents of the University of California (Oakland, CA); Meritage Pharma, Inc. (San Diego, CA)Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
Patent expiration dates:
- November 9, 2026✓
- November 9, 2026
-
Stable corticosteroid compositions
Patent 11,260,064
Issued: March 1, 2022
Inventor(s): Kasina Ramalingeswar
Assignee(s): VIROPHARMA BIOLOGICS LLCThe invention relates to pharmaceutical compositions comprising a corticosteroid and an antioxidant. The invention further relates to methods of treating, preventing, or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract comprising administering the pharmaceutical compositions comprising a corticosteroid and an antioxidant.
Patent expiration dates:
- January 10, 2039✓
- January 10, 2039
-
Compositions for the treatment of gastrointestinal inflammation
Patent 11,357,859
Issued: June 14, 2022
Inventor(s): Phillips Elaine & Hill Malcolm
Assignee(s): ViroPharma Biologics LLCProvided herein are methods for treating, preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
Patent expiration dates:
- November 12, 2028✓
- November 12, 2028
-
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Patent 11,413,296
Issued: August 16, 2022
Inventor(s): Dohil; Ranjan et al.
Assignee(s): The Regents of the University of California (Oakland, CA); Meritage Pharma, Inc. (San Diego, CA)Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
Patent expiration dates:
- November 9, 2026✓
- November 9, 2026
-
Stable corticosteroid compositions
Patent 11,564,934
Issued: January 31, 2023
Inventor(s): Kasina; Ramalingeswar
Assignee(s): ViroPharma Biologies LLC (Lexington, MA)The invention relates to pharmaceutical compositions comprising a corticosteroid and an antioxidant. The invention further relates to methods of treating, preventing, or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract comprising administering the pharmaceutical compositions comprising a corticosteroid and an antioxidant.
Patent expiration dates:
- January 10, 2039✓
- January 10, 2039
-
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Patent 8,324,192
Issued: December 4, 2012
Inventor(s): Dohil Ranjan & Bastian John & Aceves Seema S.
Assignee(s): The Regents of the University of CaliforniaProvided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
Patent expiration dates:
- August 3, 2029✓
- August 3, 2029
-
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Patent 8,497,258
Issued: July 30, 2013
Inventor(s): Dohil Ranjan & Bastian John & Aceves Seema & Phillips Elaine & Hill Malcolm
Assignee(s): The Regents of the University of CaliforniaProvided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
Patent expiration dates:
- November 9, 2026✓
- November 9, 2026
-
Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
Patent 8,679,545
Issued: March 25, 2014
Inventor(s): Dohil; Ranjan et al.
Assignee(s): The Regents of the University of California (Oakland, CA); Meritage Pharma, Inc. (San Diego, CA)Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
Patent expiration dates:
- November 9, 2026✓
- November 9, 2026
-
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Patent 8,975,243
Issued: March 10, 2015
Inventor(s): Dohil Ranjan & Bastian John & Aceves Seema S.
Assignee(s): The Regents of the University of CaliforniaProvided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
Patent expiration dates:
- November 9, 2026✓
- November 9, 2026
-
Corticosteroid compositions
Patent 9,050,368
Issued: June 9, 2015
Inventor(s): Phillips Elaine & Hill Malcolm & Deshmukh Hemant & Johnson Keith & Licalsi Cynthia
Assignee(s): Meritage Pharma, Inc.Provided herein are methods for treating, preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
Patent expiration dates:
- August 1, 2029✓
- August 1, 2029
-
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Patent 9,119,863
Issued: September 1, 2015
Inventor(s): Dohil Ranjan & Bastian John & Aceves Seema S. & Phillips Elaine & Hill Malcolm
Assignee(s): The Regents of the University of CaliforniaProvided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
Patent expiration dates:
- November 9, 2026✓
- November 9, 2026
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- February 9, 2027 - NEW PRODUCT
- February 9, 2031 - TREATMENT OF ADULT AND PEDIATRIC PATIENTS 11 YEARS OF AGE AND OLDER WITH EOSINOPHILIC ESOPHAGITIS (EOE)
More about Eohilia (budesonide)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: glucocorticoids
- Breastfeeding
- En español
Patient resources
Other brands
Pulmicort Flexhaler, Pulmicort Turbuhaler, Pulmicort Respules, Entocort EC, ... +3 more
Professional resources
Other brands
Pulmicort Flexhaler, Pulmicort Turbuhaler, Entocort EC, Tarpeyo, ... +2 more
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.